Matches in SemOpenAlex for { <https://semopenalex.org/work/W4309478921> ?p ?o ?g. }
Showing items 1 to 62 of
62
with 100 items per page.
- W4309478921 endingPage "S191" @default.
- W4309478921 startingPage "S191" @default.
- W4309478921 abstract "To date the COVID-19 pandemic is still ongoing with over 5 million registered deaths and over 1 million confirmed new cases daily Still limited information about the possible risks and protective factors for the severity and mortality of COVID-19 The initiation of the immune response in vitiligo is triggered by IFN-I production. Likewise, IFN-I and plasmacytoid dendritic cells (pDCs) play also an important role against SARS-CoV-2 virus including COVID-19 Patients with vitiligo have a genetic susceptibility profile that encodes for immune and apoptotic regulators A retrospective online questionnaire study (4 categories) was conducted in a cohort of vitiligo patients and healthy controls between November 2021 and January 2022. Categories: 1. Participant characteristics 2. COVID-19 risk factors 3. COVID-19 4. Vitiligo 209 participants completed the questionnaire 1. Do vitiligo patients clear a SARS-CoV-2 infection more efficiently compared to healthy controls? There was no significant relationship between vitiligo and developing COVID-19 [P=.930]. 35 [22%] vitiligo patients and 11 [22%] controls developed COVID-19. Univariate logistic regression models showed no confounding factors for developing COVID-19. 2. Do vitiligo patients have a higher risk of developing severe COVID-19 compared to healthy controls? There was a significant difference between having fever in vitiligo patients compared to healthy controls [p=.036], all other symptoms did not show a significant difference. 1 patient with vitiligo was admitted to the hospital, he was known with obesity and ITP. 10 vitiligo patients [28.6%] and 25 controls [45.5%] suffered from post-COVID-19 symptoms [P=.297]. The lingering symptoms between the two groups were similar: loss of smell, tiredness and shortness of breath were mostly reported. 3. Does a SARS-CoV-2 infection or COVID-19 increase the activity of vitiligo? 10 vitiligo patients reported that their vitiligo increased after COVID-19, all these patients already had an active vitiligo before or during COVID-19. 25 vitiligo patients reported that their vitiligo remained stable after COVID-19." @default.
- W4309478921 created "2022-11-28" @default.
- W4309478921 creator A5025921282 @default.
- W4309478921 creator A5053356533 @default.
- W4309478921 creator A5063727275 @default.
- W4309478921 date "2022-12-01" @default.
- W4309478921 modified "2023-10-03" @default.
- W4309478921 title "063 Autoimmunity and disease outcomes of COVID-19, lessons from vitiligo patients" @default.
- W4309478921 doi "https://doi.org/10.1016/j.jid.2022.09.072" @default.
- W4309478921 hasPublicationYear "2022" @default.
- W4309478921 type Work @default.
- W4309478921 citedByCount "0" @default.
- W4309478921 crossrefType "journal-article" @default.
- W4309478921 hasAuthorship W4309478921A5025921282 @default.
- W4309478921 hasAuthorship W4309478921A5053356533 @default.
- W4309478921 hasAuthorship W4309478921A5063727275 @default.
- W4309478921 hasBestOaLocation W43094789211 @default.
- W4309478921 hasConcept C126322002 @default.
- W4309478921 hasConcept C144301174 @default.
- W4309478921 hasConcept C151956035 @default.
- W4309478921 hasConcept C167135981 @default.
- W4309478921 hasConcept C203014093 @default.
- W4309478921 hasConcept C2779134260 @default.
- W4309478921 hasConcept C2779980618 @default.
- W4309478921 hasConcept C3008058167 @default.
- W4309478921 hasConcept C38180746 @default.
- W4309478921 hasConcept C524204448 @default.
- W4309478921 hasConcept C71924100 @default.
- W4309478921 hasConcept C77350462 @default.
- W4309478921 hasConceptScore W4309478921C126322002 @default.
- W4309478921 hasConceptScore W4309478921C144301174 @default.
- W4309478921 hasConceptScore W4309478921C151956035 @default.
- W4309478921 hasConceptScore W4309478921C167135981 @default.
- W4309478921 hasConceptScore W4309478921C203014093 @default.
- W4309478921 hasConceptScore W4309478921C2779134260 @default.
- W4309478921 hasConceptScore W4309478921C2779980618 @default.
- W4309478921 hasConceptScore W4309478921C3008058167 @default.
- W4309478921 hasConceptScore W4309478921C38180746 @default.
- W4309478921 hasConceptScore W4309478921C524204448 @default.
- W4309478921 hasConceptScore W4309478921C71924100 @default.
- W4309478921 hasConceptScore W4309478921C77350462 @default.
- W4309478921 hasIssue "12" @default.
- W4309478921 hasLocation W43094789211 @default.
- W4309478921 hasLocation W43094789212 @default.
- W4309478921 hasOpenAccess W4309478921 @default.
- W4309478921 hasPrimaryLocation W43094789211 @default.
- W4309478921 hasRelatedWork W166785664 @default.
- W4309478921 hasRelatedWork W2005036861 @default.
- W4309478921 hasRelatedWork W2340252388 @default.
- W4309478921 hasRelatedWork W2500859092 @default.
- W4309478921 hasRelatedWork W2765433625 @default.
- W4309478921 hasRelatedWork W3023752426 @default.
- W4309478921 hasRelatedWork W4242450501 @default.
- W4309478921 hasRelatedWork W4362531799 @default.
- W4309478921 hasRelatedWork W4362637518 @default.
- W4309478921 hasRelatedWork W2114915478 @default.
- W4309478921 hasVolume "142" @default.
- W4309478921 isParatext "false" @default.
- W4309478921 isRetracted "false" @default.
- W4309478921 workType "article" @default.